Trial Profile
Efficacy of the Combination of Memantine in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Young Patients to Previous Combination Therapy of Quetiapine Plus Lithium or Quetiapine Plus Aripiprazole
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2021
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Bipolar I disorders; Neurobehavioural manifestations
- Focus Therapeutic Use
- Acronyms ARIQUELI-ME
- 02 Oct 2019 Planned End Date changed from 1 Aug 2017 to 1 Sep 2020.
- 02 Oct 2019 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2020.
- 18 Dec 2015 New trial record